期刊文献+

Long-term effects of simvastatin on protection against atrial fibrillation in patients with acute myocardial infarction

Long-term effects of simvastatin on protection against atrial fibrillation in patients with acute myocardial infarction
下载PDF
导出
摘要 Objective To investigate the impact of simvastatin on blood lipid and the incidence of atrial fibrillation and ischemic-related events in patients with acute myocardial infarction accompanied by paroxysmal atrial fibrillation. Methods One hundred and three patients with acute myocardial infarction and paroxysmal atrial fibrillation were selected as subjects,and were divided into a simvastatin group and a control group. Forty-five patients were in the simvastatin group,who took simvastatin 20mg/d orally for 18 months;fifty-eight patients were in the control group,and received conventional therapy except for statins. All patients were followed up for 18 months. The level of blood lipid,recurrence rate of paroxysmal atrial fibrillation,incidence rate of persistent or permanent atrial fibrillation,and the ischemic-related events were investigated and compared between the two groups. Results ① The levels of blood lipids did not change significantly in the control group(P>0.05) ;concentrations of total cholesterol(TC) and low density lipoprotein cholesterol(LDL-C) decreased significantly after treatment of simvastatin(P<0.05) . ② Recurrence of atrial fibrillation was observed in five patients during 18 months follow-up in the simvastatin group(11.1%) ,whereas it occurred in 14 patients of the control group(24. 1%,P<0.05) ;the occurrence rate of persistent or permanent atrial fibrillation in the simvastatin group was 4.4%,which was lower than that of control(12.1%,P<0.05) . ③ Nine patients had ischemic-related events in the simvastatin group(20.0%) ,with three heart failures(6.6%) ,two rehospitalizations for deterioration of coronary heart diseases(4.4%) ,three cardiac deaths(6.6%) ,and one cerebral stroke(2.2%) ,which was lower evidently than in the control group(41.4%,P<0.05) . Conclusions Simvastatin can not only decrease the levels of serum TC and LDL-C but also prevent the occurrence of atrial fibrillation and ischemic-related events. Objective To investigate the impact of simvastatin on blood lipid and the incidence of atrial fibrillation and ischemic-related events in patients with acute myocardial infarction accompanied by paroxysmal atrial fibrillation. Methods One hundred and three patients with acute myocardial infarction and paroxysmal atrial fibrillation were selected as subjects,and were divided into a simvastatin group and a control group. Forty-five patients were in the simvastatin group,who took simvastatin 20mg/d orally for 18 months;fifty-eight patients were in the control group,and received conventional therapy except for statins. All patients were followed up for 18 months. The level of blood lipid,recurrence rate of paroxysmal atrial fibrillation,incidence rate of persistent or permanent atrial fibrillation,and the ischemic-related events were investigated and compared between the two groups. Results ① The levels of blood lipids did not change significantly in the control group(P>0.05) ;concentrations of total cholesterol(TC) and low density lipoprotein cholesterol(LDL-C) decreased significantly after treatment of simvastatin(P<0.05) . ② Recurrence of atrial fibrillation was observed in five patients during 18 months follow-up in the simvastatin group(11.1%) ,whereas it occurred in 14 patients of the control group(24. 1%,P<0.05) ;the occurrence rate of persistent or permanent atrial fibrillation in the simvastatin group was 4.4%,which was lower than that of control(12.1%,P<0.05) . ③ Nine patients had ischemic-related events in the simvastatin group(20.0%) ,with three heart failures(6.6%) ,two rehospitalizations for deterioration of coronary heart diseases(4.4%) ,three cardiac deaths(6.6%) ,and one cerebral stroke(2.2%) ,which was lower evidently than in the control group(41.4%,P<0.05) . Conclusions Simvastatin can not only decrease the levels of serum TC and LDL-C but also prevent the occurrence of atrial fibrillation and ischemic-related events.
机构地区 Heart Center
出处 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2007年第3期144-147,共4页 老年心脏病学杂志(英文版)
关键词 simvastation ATRIAL FIBRILLATION acute myocardial INFARCTION simvastation atrial fibrillation acute myocardial infarction
  • 相关文献

参考文献18

  • 1[1]Goldberg RJ,Yarzebski J,Lessard D,et al.Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction:a community-wide perspective.Am Heart J 2002; 143:519-27.
  • 2[2]Rathore SS,Berger AK,Weinfurt KP,et al.Acute myocardial infarction complicated by atrial fibrillation in the elderly:prevalence and outcomes.Circulation 2000; 101:969-74.
  • 3[3]Crenshaw BS,Ward SR,Granger CB,et al.Atrial fibrillation in the setting of acute myocardial infarction:the GUSTO-Ⅰexperience:Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.J Am Coll Cardiol 1997; 30:406-13.
  • 4[4]Wong CK,White HD,Wilcox RG,et al.New atrial fibrillation after acute myocardial infarction independently predicts death:the GUSTO-Ⅲ experience.Am Heart J 2000; 140:878-85.
  • 5[5]Kinjo K,Sato H,Ohnishi Y,et al.Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention Am J Cardiol 2003; 92:1150-4.
  • 6[6]Wong CK,White HD,Wilcox RG,et al.Significance of atrial fibrillation during acute myocardial infarction,and its current management:insights from the GUSTO-3 trial.Card Electrophysiol Rev 2003; 7:201-7.
  • 7[7]Lehto M,Snapinn S,Dickstein K,et al.Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction:the OPTIMAAL experience.Eur Heart J 2005;26:350-6.
  • 8[8]Atrial fibrillation post-myocardial infarction:frequency,consequences,and management.Curr Heart Fail Rep 2004; 1:149-55.
  • 9[9]Athyros VG,Papageorgiou AA,Mercouris BR,et al.Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention.The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.Curr Med Res Opin 2002;18:220-8.
  • 10[10]Maron DJ,Fazio S,Linton MF.Current perspectives on statins.Circulation 2000; 101:207-13.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部